Xenon Pharmaceuticals

Xenon said at the Wells Fargo Healthcare Conference that it plans to file the New Drug Application (NDA) for Azetukalner later this month and expects all four doses (10, 15, 20, 25 mg) to be included in the prescribing information. The company intends a premium pricing strategy with a single price across all strengths and is building a commercial team of about 150 employees, including a field force of roughly 75, to reduce market access barriers. Xenon emphasized the novel Kv7 mechanism of action but anticipates a slow, stepwise launch pattern for epilepsy products; global approval plans will be supported by the ongoing Phase III X‑TOLE3 study. In parallel, Xenon is advancing programs in depression (X‑NOVA) and NaV1.7 pain, and aims to have a fully integrated commercial biopharma structure by the end of 2027. » Mere på de.investing.com

Xenon Pharmaceuticals will present six Azetukalner presentations at the 16th European Epilepsy Congress (5–9 September 2026, Athens), including an oral presentation of the phase‑3 X-TOLE2 study in focal onset seizures. The data include results from the randomized, double‑blind, placebo‑controlled X-TOLE2 (380 participants; Azetukalner 25 mg or 15 mg vs. placebo) and findings from patients with at least 48 months of participation in the open‑label extension. In addition, mechanistic posters will show data on possible additive effects in combination with common antiseizure medications and in‑vivo evidence; Azetukalner is a potassium channel opener in development for epilepsy, major depressive disorder and bipolar depression. » Mere på de.investing.com

Xenon Pharmaceuticals’ share rose to a record high of $63.96, marking a yearly increase of 102.36% and a YTD gain of 35%, with market capitalization around $6.2 billion. Analysts still see strong buy consensus and maintain a high price target of $100; the stock trades near its fair value. Q1 2026 results painted a mixed picture: EPS of -$1.17 slightly beat estimates, while no revenue was reported, missing expectations. » Mere på de.investing.com